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Recent advances in our understanding of the
autoimmune basis of alopecia areata provide an
opportunity to create novel effective pharmaceutical
interventions. The current lack of approved therapies
for alopecia areata presents a high unmet medical
need, as well as a potentially attractive market
opportunity. From an industry perspective, achieving
clinical proof of concept (PoC) gates investments into
larger approval studies. Recent investigator-initiated
experience suggests that it may be possible to
demonstrate rigorous PoC for new therapies in an
attractive time frame with relatively fewer patients
than were believed necessary in the past. However,
the lack of prior regulatory approval precedent for
pharmaceuticals to treat alopecia areata poses signifi-
cant development challenges, and early interaction
with the FDA and other stakeholders will be critically
important in evaluating the path to approval and
reimbursement for new treatments for this indication.
This paper presents a brief industry perspective on
the potential development of new alopecia areata
therapeutics.
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INTRODUCTION
Recent advances in our understanding of the autoimmune
basis of alopecia areata provide an opportunity to create novel
effective pharmaceutical interventions. The development and
successful commercialization of new medicines for alopecia
areata will require collaboration between industry, patients,
academia, regulators, and payors. From an industry perspec-
tive, it is important to carefully evaluate the potential paths to
regulatory approval, as well as factors that will contribute to
commercial success, such as reimbursement. The lack of
regulatory approval precedent poses significant development
challenges. However, the clear unmet need for effective,
well-tolerated, and approved therapies for this underserved
indication and precedents for reimbursement in analogous
dermatological indications provide a compelling rationale for
drug development in alopecia areata.
DEVELOPMENT TRACTABILITY: PROOF OF CONCEPT
AND REGULATORY APPROVAL
Key factors to consider when developing a pharmaceutical in
a new therapeutic area include time and cost to proof of
concept (PoC) and path to regulatory approval. For industry,
PoC is the demonstration of desired effect that provides
support for investing additional funds. PoC as a term most
frequently refers to the demonstration of clinical efficacy in a
phase 2 study in the affected patient population.
Historically, achieving PoC in alopecia areata has been
challenging. In a 2008 Cochrane review, 17 trials were
included with a total of 540 participants, assessing a wide
range of therapeutic options. The authors found that ‘‘Overall,
none of the interventions showed significant treatment benefit
in terms of hair growth when compared with placebo.’’ This
difficulty was attributed to a lack of robust, well-designed
trials, and substantial variation in individual patient response
to therapy (Delamere et al., 2008). In addition, some patients
with alopecia areata show patterns of spontaneous remission
(Harries et al., 2010), which can complicate effect
interpretation.
However, new research into the T-cell-mediated mechan-
ism of disease for alopecia areata supports potential for
achieving PoC within a reasonable time frame and budget.
Recent investigator experience has demonstrated promising
patient responses to investigational drugs in o6 months
(Craiglow and King, 2014; Xing et al., 2014). Given the
profound responses seen in some patients, it may be possible
for the industry to demonstrate PoC for new therapies in an
attractive time frame with relatively fewer patients than was
possible in the past.
Time and cost to PoC holds particular weight in a cost–
benefit analysis of pursuing alopecia areata versus other
possible indications, but it is only one element of an overall
path to regulatory approval. The broader long-term path is also
a critical development consideration for industry when eval-
uating new therapeutic areas. It is estimated that only 8% of
drugs make it from molecule selection to regulatory approval,
with an estimated time frame of B8 years (http://www.
forbes.com/sites/brucebooth/2014/11/21/a-billion-here-a-bil-
lion-there-the-cost-of-making-a-drug-revisited/; DiMasi et al.,
2010; Kaitin and DiMasi, 2011). Owing to the high risk of
failure, and the associated expense and opportunity cost,
it is important to carefully evaluate the key components
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of the broader development path, including but not limited to
clinical trials, size of patient safety database, suppor-
tive non-clinical pharmacology and toxicology, drug
manufacturing, and formulation.
As there are no approved therapies for alopecia areata, the
approval pathway and registration requirements are less clear
than in indications with established precedent. Likewise,
because alopecia areata affects a large population and is not
generally considered a life-threatening disease (https://
www.naaf.org; Messenger, 2015) the efficacy and safety
profile of new therapies will be critically important. As a
result, early interaction with the Food and Drug
Administration (FDA) will be key to defining a tractable
regulatory approval pathway. As part of these interactions, it
will be particularly important to elucidate the substantial
impact of alopecia areata on patients’ quality of life and
psychological health (Sellami et al., 2014).
Although there is no regulatory precedent for drug approval,
there are substantial advantages to pursuing clinical trials in
alopecia areata. Two of the greatest advantages are the large,
highly motivated patient population, and the highly engaged
academic and clinician researchers. Trial enrollment and
retention can be a major impediment to efficient drug
development. Owing to the massive unmet need for effective,
well-tolerated, convenient therapies for alopecia areata, and
the devastating psychological impact of the disease, both
patients and researchers are enthusiastic about trial participa-
tion. Similarly, the presence and support of a strong, active
patient foundation, such as the National Alopecia Areata
Foundation (NAAF), can be of great help in the development
of new therapies.
POST-APPROVAL LAUNCH AND ACCESS TO
MEDICATION
It is imperative for companies to facilitate access to newly
launched drug for patients, while balancing the needs of other
stakeholders. In evaluating new therapeutic areas, industry
generally considers three elements of commercial positioning:
competitive environment, patient population and usage, and
reimbursement.
As described, the current competitive environment for a
new effective therapy for alopecia areata is attractive. There
are no approved therapies, no cure, and no universally proven
therapy that induces and sustains remission (https://www.
naaf.org; Delamere et al., 2008).
However, there are challenges to evaluating disease
prevalence and forecasting usage of a new pharmaceutical
in alopecia areata. Because the disease may independently
remit, it is challenging to predict how long patients will take a
new therapy. It is also unclear how new targeted agents will
be used across patient populations of different disease severity.
As targeted therapies are still early in exploration, mainte-
nance of effect and long-term dosing requirements are also
somewhat unclear. The lack of approved therapies also means
that there are limited benchmarks for evaluating the balance of
efficacy and cost. Similarly, patient and physician tolerance
for side effects and safety considerations for potent agents will
require assessment. Clearly, the overall development pathway
for a new pharmaceutical will require careful planning to
address some of these topics.
Finally, but importantly, reimbursement potential has
become a significant factor for both evaluation of new drugs
and indication selection, particularly over the past 5 years
(DiMasi et al., 2010). The critical question for pharmaceutical
companies has largely shifted from ‘‘Can this get approved?’’
to ‘‘Will payors cover it?’’ The pace of change in the
reimbursement environment has been significant in Europe,
but reimbursement has also become the major consideration
in the USA and other major markets.
Alopecia areata has complex reimbursement positioning; as
discussed, it affects a large population and can be psycholo-
gically devastating, but is also not considered to be a life-
threatening disease. In light of potential for highly effective
targeted therapies, there is a compelling case to be made for
insurance reimbursement, especially as payors move toward
clinically meaningful improvement in patient quality of life as
a leading indicator to justify costs. Furthermore, there are
significant indirect benchmarks from other dermatological
indications for reimbursement precedent, particularly in psor-
iasis and acne.
One such example is isotretinoin, a highly potent agent with
a complex side effect profile (http://www.rochecanada.com/
fmfiles/re7234008/Research/ClinicalTrialsForms/Products/
ConsumerInformation/MonographsandPublicAdvisories/
Accutane/Accutane_PM_E.pdf), which is used to treat a
cosmetically devastating, generally non-life threatening
dermatological condition. Isotretinoin is labeled for severe
nodular acne, and carries a black-box warning for teratogeni-
city. As of 2009, Accutane had been used by 413 million
patients worldwide (http://www.latimes.com/nation/la-
sci-accutane7-2009nov07-story.html), and prescriptions are
frequently covered by insurance payors. Because the
psychological impact parallels between severe acne and
alopecia areata (Ayer and Burrows, 2006; Sellami et al.,
2014) this comparison provides a meaningful reimbursement
benchmark.
Alopecia areata is a psychologically destructive autoim-
mune disease affecting the quality of life for millions of
patients on a daily basis. The lack of regulatory approval
precedent poses challenges for constructing a development
plan. However, the clear unmet need for approved,
well-tolerated, novel therapies in this underserved patient
population, the recent groundbreaking discoveries in biologi-
cal mechanisms, and precedents for insurance reimbursement
provide a compelling rationale for drug development.
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